GSK/Theravance's Relvar Ellipta gets CHMP yes
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline and Theravance's Relvar Ellipta have received a positive approval recommendation from the European Medicines Agency's CHMP for the treatment of asthma and chronic obstructive pulmonary disease (COPD).